ASCO 2022: Redefining the Treatment Landscape in Metastatic Breast Cancer

Tarah J. Ballinger, MD


June 10, 2022

Tarah J. Ballinger, MD, provides an update on the exciting advances in metastatic breast cancer (mBC) presented at the 2022 ASCO Annual Meeting. First, Dr Ballinger remarks on the results of the PALOMA-2 study, which showed that overall survival (OS) was not statistically significant for palbociclib plus letrozole compared with placebo plus letrozole in the first-line treatment of postmenopausal women with ER+, HER2-negative mBC.

Next, Dr Ballinger reviews the results from the MAINTAIN trial, which showed a 2.5-month improvement in progression-free survival (PFS) in patients with HR+ mBC who progressed on a CDK4/6 with hormone therapy and switched to another CDK4/6 inhibitor, ribociclib, highlighting the need for more effective therapies for patients in post-CDK4/6 progression.

Dr Ballinger also looks at the results of the TROPiCS-2 study, which showed that the antibody-drug conjugate (ADC) sacituzumab govitecan provided 1.5 months of PFS in a heavily pretreated population with hormone-refractory mBC, providing more options for these patients.

Finally, Dr Ballinger reviews the practice-changing results of the DESTINY-04 trial, which evaluated patients with mBC with low expression of HER2 who were randomly assigned to receive the ADC trastuzumab deruxtecan or physicians' choice of chemotherapy. Patients who received trastuzumab deruxtecan improved their PFS by 5 months and OS by 6.5 months, which, according to Dr Ballinger, will redefine the treatment landscape for mBC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.